Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Behzad Aghazadeh acquired 2,383,333 shares of Scribe Therapeutics stock in a transaction dated Friday, July 24th. The stock was purchased at an average cost of $15.15 per share, for a total transaction of $36,107,494.95. Following the completion of the purchase, the director owned 3,080,983 shares in the company, valued at approximately $46,676,892.45. The trade was a 341.62% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Behzad Aghazadeh also recently made the following trade(s):
- On Tuesday, July 28th, Behzad Aghazadeh bought 7,905 shares of Scribe Therapeutics stock. The shares were purchased at an average cost of $18.25 per share, with a total value of $144,266.25.
Scribe Therapeutics Trading Up 11.1%
SCTX stock opened at $20.40 on Friday. Scribe Therapeutics Inc. has a 1-year low of $17.31 and a 1-year high of $25.49.
Recommended Stories
- Five stocks we like better than Scribe Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
